Stay updated with breaking news from Acelyrin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oracle's revenue outlook disappoints, Apple kicks off its annual fall launch event, Tesla falls a day after surging 10%, and WestRock signs an agreement to...
ACELYRIN, INC. (SLRN) announced top-line results from Part B of a Phase 2b/3 trial evaluating izokibep for the treatment of moderate-to-severe Hidradenitis Suppurativa.
By Ben Glickman Shares of Acelyrin fell after-hours after the company said its skin drug candidate's primary endpoint didn't meet statistical significance....
Acelyrin (NASDAQ:SLRN – Free Report) had its price target lifted by Morgan Stanley from $29.00 to $39.00 in a research report report published on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has an overweight rating on the stock. Several other research firms also recently issued reports on SLRN. Piper Sandler assumed coverage on Acelyrin […]
HC Wainwright started coverage on shares of Acelyrin (NASDAQ:SLRN – Free Report) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating and a $44.00 price target on the stock. HC Wainwright also issued estimates for Acelyrin’s Q3 2023 earnings at ($0.29) EPS, Q4 2023 earnings at […]